Clinical Research Directory
Browse clinical research sites, groups, and studies.
Phase 1/2 Study of FRF-001, an AAV-9 Gene Therapy, in Patients With FOXG1 Syndrome (FS)
Sponsor: FOXG1 Research Foundation
Summary
The goal of this clinical trial is to learn if FRF-001 is a safe, tolerable, and efficacious treatment for children and adults with FOXG1 syndrome.
Official title: An Open-Label First-in-Human Phase 1/2 Study to Evaluate the Safety, Tolerability, and Efficacy of FRF-001, an AAV-9 Gene Therapy Administered by Intracerebroventricular Injection in Participants With FOXG1 Syndrome
Key Details
Gender
All
Age Range
2 Years - 20 Years
Study Type
INTERVENTIONAL
Enrollment
12
Start Date
2026-07-20
Completion Date
2029-12
Last Updated
2026-07-24
Healthy Volunteers
No
Conditions
Interventions
FRF-001
AAV-9 gene therapy delivered by intracerebroventricular injection
Locations (1)
Texas Children's Hospital (Baylor College of Medicine)
Houston, Texas, United States